Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: A randomized, double-blind, placebo-controlled study

Journal of Crohn's and Colitis

Volumn 8, Issue 11, 2014, Pages 1471-1479

  Beigel, Florian ^a   Teich, Niels ^b   Howaldt, Stefanie ^c   Lammert, Frank ^d   Maul, Jochen ^e   Breiteneicher, Simone ^a   Rust, Christian ^a,f   Göke, Burkhard ^a   Brand, Stephan ^a   Ochsenkühn, Thomas ^a,g  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Internal Practice   (Germany)

^c Internal Practice   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f KRANKENHAUS BARMHERZIGE BRÜDER   (Germany)

^g Isar Medizin Zentrum   (Germany)

Author keywords

Bile acid malabsorption; Colesevelam; Crohn's disease; Diarrhea

Indexed keywords

COLESEVELAM; PLACEBO; ALLYLAMINE; BILE ACID; CHOLEST 4 EN 3 ONE; HYPOCHOLESTEROLEMIC AGENT;

ACNE; ADULT; AGED; ARTICLE; BILE ACID MALABSORPTION ASSOCIATED DIARRHEA; BLOATING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYELID EDEMA; FECES COMPOSITION; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; LIQUID FECES; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPLICATION; FECES; MALABSORPTION SYNDROMES; METABOLISM;

ADULT; AGED; ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; CHOLESTENONES; CROHN DISEASE; DIARRHEA; DOUBLE-BLIND METHOD; FECES; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALABSORPTION SYNDROMES; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84927797579     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.05.009     Document Type: Article

References (31)

1. Bernell O., Lapidus A., Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. Br J Surg 2000, 87(12):1697-1701.
2. Johnston I., Nolan J., Pattni S.S., Walters J.R. New insights into bile acid malabsorption. Curr Gastroenterol Rep 2011, 13(5):418-425.
3. Iwamoto J., Saito Y., Honda A., Miyazaki T., Ikegami T., Matsuzaki Y. Bile acid malabsorption deactivates pregnane X receptor in patients with Crohn's disease. Inflamm Bowel Dis 2013, 19(6):1278-1284.
4. Glas J., Seiderer J., Fischer D., Tengler B., Pfennig S., Wetzke M., et al. Pregnane X receptor (PXR/NR1I2) gene haplotypes modulate susceptibility to inflammatory bowel disease. Inflamm Bowel Dis 2011, 17(9):1917-1924.
5. Vijayvargiya P., Camilleri M., Shin A., Saenger A. Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol 2013, 11(10):1232-1239.
6. Walters J.R. Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder. Expert Rev Gastroenterol Hepatol 2010, 4(5):561-567.
7. Eusufzai S. Bile acid malabsorption: mechanisms and treatment. Dig Dis 1995, 13(5):312-321.
8. Robinson D.M., Keating G.M. Colesevelam: a review of its use in hypercholesterolemia. Am J Cardiovasc Drugs 2007, 7(6):453-465.
9. Younk L.M., Davis S.N. Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol 2012, 8(4):515-525.
10. Davidson M.H., Dillon M.A., Gordon B., Jones P., Samuels J., Weiss S., et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999, 159(16):1893-1900.
11. Kuiper E.M., van Erpecum K.J., Beuers U., Hansen B.E., Thio H.B., de Man R.A., et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010, 52(4):1334-1340.
12. Odunsi-Shiyanbade S.T., Camilleri M., McKinzie S., Burton D., Carlson P., Busciglio I.A., et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010, 8(2):159-165.
13. Wong B.S., Camilleri M., Carlson P.J., Odunsi-Shiyanbade S.T., McKinzie S., Busciglio I.A., et al. Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea. Dig Dis Sci 2012, 57(5):1222-1226.
14. Beigel F., Seiderer J., Göke B., Ochsenkühn T., Brand S., Howaldt S. Efficacy and safety of colesevelam (cholestagel®) for the treatment of bile acid malabsorption in patients with crohn's disease after ileocoecal resection. Gut 2009, 58(Suppl. II):A470.
15. Knox J.F., Rose D., Emmons J., et al. Colesevelam for the treatment of bile acid diarrhea induced diarrhea in Crohn's disease: patients intolerant of cholestyramine. Gastroenterology 2004, 5(A-628):W1399.
16. Wedlake L., Thomas K., Lalji A., Anagnostopoulos C., Andreyev H.J. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. Clin Ther 2009, 31(11):2549-2558.
17. Sauter G.H., Munzing W., von Ritter C., Paumgartner G. Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum. Dig Dis Sci 1999, 44(1):14-19.
18. Sauter G., Berr F., Beuers U., Fischer S., Paumgartner G. Serum concentrations of 7alpha-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans. Hepatology 1996, 24(1):123-126.
19. Freudenberg F., Gothe F., Beigel F., Rust C., Koletzko S. Serum 7-alpha-hydroxy-4-cholesten-3-one as a marker for bile acid loss in children. J Pediatr 2013, 163(5):1367-1371. [e1].
20. Lewis S.J., Heaton K.W. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997, 32(9):920-924.
21. Jenkinson C., Coulter A., Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993, 306(6890):1437-1440.
22. Kurien M., Evans K.E., Leeds J.S., Hopper A.D., Harris A., Sanders D.S. Bile acid malabsorption: an under-investigated differential diagnosis in patients presenting with diarrhea predominant irritable bowel syndrome type symptoms. Scand J Gastroenterol 2011, 46(7-8):818-822.
23. Nyhlin H., Merrick M.V., Eastwood M.A. Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT. Gut 1994, 35(1):90-93.
24. Wong B.S., Camilleri M., Carlson P., McKinzie S., Busciglio I.A., Bondar O., et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2012, 10(9):1009-1015. [e3].
25. de Winter J.C.F. Using the Student's t-test with extremely small sample sizes. Pract Assess Res Eval 2013, 18(10):1-12.
26. Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., Michalsen A., Dobos G.J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008, 103(1):162-169.
27. Goldfine A.B., Fonseca V.A., Jones M.R., Wang A.C., Ford D.M., Truitt K.E. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res 2010, 42(1):23-30.
28. Borghede M.K., Schlutter J.M., Agnholt J.S., Christensen L.A., Gormsen L.C., Dahlerup J.F. Bile acid malabsorption investigated by selenium-75-homocholic acid taurine ((75)SeHCAT) scans: causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhoea. Eur J Intern Med 2011, 22(6):e137-e140.
29. Barkun A.N., Love J., Gould M., Pluta H., Steinhart H. Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment. Can J Gastroenterol 2013, 27(11):653-659.
30. Pattni S.S., Brydon W.G., Dew T., et al. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention. Aliment Pharmacol Ther 2013, 38(8):967-976.
31. Lenicek M., Duricova D., Komarek V., et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm Bowel Dis 2010, 17(6):1322-1327.